LEAP-008: Lenvatinib and Pembrolizumab after Platinum and Immunotherapy
Condition: Non-Small Cell Lung Cancer
Sponsor: Merck Sharp & Dohme Corp.
Protocol: MK-7902-008: A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus docetaxel in previously treated participants with metastatic non- small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and immunotherapy.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.